Cellectis (NASDAQ:CLLS) Stock Passes Above 50-Day Moving Average of $2.42

Cellectis S.A. (NASDAQ:CLLSGet Rating) shares passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.42 and traded as high as $2.51. Cellectis shares last traded at $2.50, with a volume of 155,024 shares traded.

Wall Street Analyst Weigh In

CLLS has been the topic of several analyst reports. Citigroup upped their target price on shares of Cellectis from $34.00 to $36.00 in a report on Thursday, August 18th. StockNews.com lowered shares of Cellectis from a “hold” rating to a “sell” rating in a report on Friday. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $15.17.

Cellectis Trading Up 15.2 %

The business’s fifty day simple moving average is $2.42 and its 200 day simple moving average is $2.89. The company has a current ratio of 2.65, a quick ratio of 2.65 and a debt-to-equity ratio of 0.10. The stock has a market cap of $113.93 million, a P/E ratio of -1.09 and a beta of 2.01.

Institutional Investors Weigh In On Cellectis

A number of hedge funds have recently added to or reduced their stakes in CLLS. Envestnet Asset Management Inc. grew its holdings in Cellectis by 19.2% during the 1st quarter. Envestnet Asset Management Inc. now owns 20,501 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 3,305 shares during the last quarter. Princeton Capital Management LLC bought a new position in shares of Cellectis in the 1st quarter valued at about $50,000. Oppenheimer & Co. Inc. bought a new position in shares of Cellectis in the 1st quarter valued at about $339,000. State Street Corp boosted its stake in shares of Cellectis by 3.7% in the 1st quarter. State Street Corp now owns 119,561 shares of the biotechnology company’s stock valued at $543,000 after purchasing an additional 4,297 shares during the last quarter. Finally, Jane Street Group LLC boosted its stake in shares of Cellectis by 166.5% in the 1st quarter. Jane Street Group LLC now owns 603,253 shares of the biotechnology company’s stock valued at $2,789,000 after purchasing an additional 376,862 shares during the last quarter. Institutional investors own 23.83% of the company’s stock.

About Cellectis

(Get Rating)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.

Read More

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.